In addition to increasing IDE expression, Isorhynchophylline can also inhibit the activation of microglia and astrocytes, reduce tau hyperphosphorylation and neuroinflammation, and improve cognitive impairment, which has a good potential for further development into drug therapy for AD (139). This evidence concerns the gene MAPT and Alzheimer disease.